SUPPLEMENTAL MATERIALS.docx (353.99 kB)
Download file

Supplementary Material – Real-World Cost-Effectiveness of Primary Prophylaxis with G-CSF Biosimilars in Patients at Intermediate/High FN Risk

Download (353.99 kB)
figure
posted on 31.03.2022, 07:47 authored by Figshare Future Science GroupFigshare Future Science Group, Paul Cornes, John Kelton, Rongzhe Liu, Omer Zaidi, Jennifer Stephens, Jingyan Yang

Supplemental Figure 1. Algorithm for assessing FN risk and the need for primary prophylactic G-CSF

Supplemental Figure 2. PSA Cost-Effectiveness Acceptability Curves, by Outcome and Risk Group

Supplemental Figure 3. OWSA Tornado Diagrams for Incremental Cost-effectiveness Ratios, By Outcome

Funding

Pfizer Inc

History